Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926575 | 0.89 | POLB (0.44) | KDM4EL3MBTL1HPGDANO1P2RX7 | |
| SCHEMBL9926536 | 0.88 | KDM4E (0.40) | KDM4EL3MBTL1HPGDANO1P2RX7 | |
| SCHEMBL9926581 | 0.87 | CA1 (0.48) | KDM4EHPGDANO1P2RX7ALDH1A1 | |
| SCHEMBL9926670 | 0.82 | PIK3CD (0.40) | KDM4EANO1P2RX7ALDH1A1HTT | |
| SCHEMBL9926582 | 0.81 | IDO1 (0.38) | KDM4EL3MBTL1ANO1P2RX7ALDH1A1 | |
| SCHEMBL9926626 | 0.81 | P2RX7 (0.41) | P2RX7 | |
| SCHEMBL9926578 | 0.77 | P2RX7 (0.41) | P2RX7 | |
| SCHEMBL13702382 | 0.77 | L3MBTL1 (0.64) | KDM4EL3MBTL1HPGDANO1P2RX7 | |
| SCHEMBL9926555 | 0.76 | MEP1B (0.41) | KDM4EL3MBTL1HPGDP2RX7ALDH1A1 | |
| SCHEMBL9926557 | 0.76 | CXCL8 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | KDM4E 983/4885L3MBTL1 676/4885HPGD 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.